Cargando…

Correction to: Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn‘s disease

Detalles Bibliográficos
Autores principales:	Hong, Qijin, Shen, Jun, Feng, Qi, Zheng, Qing, Qiao, Yuqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101915/ https://www.ncbi.nlm.nih.gov/pubmed/35562662 http://dx.doi.org/10.1186/s12876-022-02297-8

Ejemplares similares

Prevalence and predictors of non-alcoholic liver disease on MRI among patients with Crohn's disease
por: Hong, Qijin, et al.
Publicado: (2022)

MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
por: Feng, Jing, et al.
Publicado: (2022)

Correction: Global prevalence, incidence, and outcomes of alcohol related liver diseases: a systematic review and meta-analysis
por: Niu, Xuanxuan, et al.
Publicado: (2023)

Correction to: “Non alcoholic fatty liver disease and eNOS dysfunction in humans”
por: Persico, Marcello, et al.
Publicado: (2017)

Burden and Predictors of Non-Alcoholic Fatty Liver Disease in a Retrospective Cohort of Patients With Crohn’s Disease
por: Abomhya, Ahmed, et al.
Publicado: (2022)

Relating the transcriptome and microbiome by paired terminal ileal Crohn disease
por: Cai, Chenwen, et al.
Publicado: (2021)

Correction: The expanding role of fish models in understanding non-alcoholic fatty liver disease
Publicado: (2014)

Correction: Insights into the genetic epidemiology of Crohn's and rare diseases in the Ashkenazi Jewish population
por: Rivas, Manuel A., et al.
Publicado: (2019)

Correction to: Feasibility of intraoperative ultrasound of the small bowel during Crohn’s disease surgery
por: Celentano, V., et al.
Publicado: (2023)

Correction: Extracellular vesicles package dsDNA to aggravate Crohn’s disease by activating the STING pathway
por: Zhao, Fan, et al.
Publicado: (2021)

Correction: Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
Publicado: (2014)

Correction to: Disease recurrence in patients with Crohn’s disease after biologic therapy or surgery: a meta-analysis
por: Kneißl, Sarah, et al.
Publicado: (2022)

Correction: CD40: Novel Association with Crohn's Disease and Replication in Multiple Sclerosis Susceptibility
por: Blanco-Kelly, Fiona, et al.
Publicado: (2010)

Correction to: A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels
por: Zhang, Pengzi, et al.
Publicado: (2020)

Correction to: Proteomic identification and characterization of hepatic glyoxalase 1 dysregulation in non-alcoholic fatty liver disease
por: Spanos, Christos, et al.
Publicado: (2018)

Correction to: Prevalence of prolonged QT interval in patients with HCV-related chronic liver disease
por: Gaafar, Ahmed E., et al.
Publicado: (2019)

Correction: Exploration of Serum Proteomic Profiling and Diagnostic Model That Differentiate Crohn’s Disease and Intestinal Tuberculosis
por: Zhang, Fenming, et al.
Publicado: (2019)

Correction to: Prevalence and predictors of alcohol use among adult males in Ethiopia: multilevel analysis of Ethiopian Demographic and Health Survey 2016
por: Tessema, Zemenu Tadesse, et al.
Publicado: (2020)

Correction: Prevalence and predictors for sustained remission in rheumatoid arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2019)

Correction to: Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission
por: Lin, Xiaoqing, et al.
Publicado: (2020)

Correction: Free Fatty Acids Differentially Downregulate Chemokines in Liver Sinusoidal Endothelial Cells: Insights into Non-Alcoholic Fatty Liver Disease.
por: McMahan, Rachel H., et al.
Publicado: (2016)

Correction: Exploring the effect of Yinzhihuang granules on alcoholic liver disease based on pharmacodynamics, network pharmacology and molecular docking
por: Tan, Yingying, et al.
Publicado: (2023)

Correction to: Transient receptor potential ankyrin 1 promoter methylation and peripheral pain sensitivity in Crohn’s disease
por: Gombert, Sara, et al.
Publicado: (2021)

Correction to: Associations between MRI T1 mapping, liver stiffness, quantitative MRCP, and laboratory biomarkers in children and young adults with autoimmune liver disease
por: Mahalingam, Neeraja, et al.
Publicado: (2022)

Construction of a neural network diagnostic model and investigation of immune infiltration characteristics for Crohn’s disease
por: Yang, Yufei, et al.
Publicado: (2022)

Correction to: A Computational Platform Integrating a Mechanistic Model of Crohn’s Disease for Predicting Temporal Progression of Mucosal Damage and Healing
por: Venkatapurapu, Sai Phanindra, et al.
Publicado: (2022)

Correction to: Effect of Lycium barbarum polysaccharide supplementation in non-alcoholic fatty liver disease patients: study protocol for a randomized controlled trial
por: Gao, Lu-Lu, et al.
Publicado: (2021)

Correction: Role of IRAK-M in Alcohol Induced Liver Injury
por: Wang, Yipeng, et al.
Publicado: (2014)

Author Correction: Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis
por: Waghorn, Philip A., et al.
Publicado: (2021)

Correction: Experimental non-alcoholic fatty liver disease causes regional liver functional deficits as measured by the capacity for galactose metabolism while whole liver function is preserved
por: Eriksen, Peter Lykke, et al.
Publicado: (2023)

Correction to: Gadoxetic acid‑enhanced MRI in primary sclerosing cholangitis: added value in assessing liver function and monitoring disease progression
por: Elkilany, Aboelyazid, et al.
Publicado: (2021)

Author Correction: Non-alcoholic fatty liver disease and cerebral small vessel disease in Korean cognitively normal individuals
por: Jang, Hyemin, et al.
Publicado: (2019)

Correction to ‘Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy’
por: Wan, S., et al.
Publicado: (2019)

Correction: Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn's Disease
por: Danoy, Patrick, et al.
Publicado: (2011)

Correction: Association of Variants at 1q32 and STAT3 with Ankylosing Spondylitis Suggests Genetic Overlap with Crohn's Disease
por: Danoy, Patrick, et al.
Publicado: (2011)

Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2015)

Correction: The association between environmental exposures during childhood and the subsequent development of Crohn's disease: A score analysis approach
por: Sabe, Victor Tinashe, et al.
Publicado: (2017)

Correction: Acute Infectious Gastroenteritis Potentiates a Crohn's Disease Pathobiont to Fuel Ongoing Inflammation in the Post-Infectious Period
por: Small, Cherrie L., et al.
Publicado: (2018)

Correction: Infliximab for pediatric patients with Crohn’s disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan
por: Tajiri, Hitoshi, et al.
Publicado: (2022)

Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran
por: AMIRKALALI, Bahareh, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7p272vn2fk3k2b33jgerm3614v